Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer.
OBJECTIVE
Bone metastasis is a major complication of advanced breast cancer. The present prospective case-control study investigated the involvement of microRNA (miR)-10b in the development of bone metastasis arising from primary breast carcinoma.


METHODS
Serum miR-10b concentrations  were determined by quantitative real-time reverse transcription-polymerase chain reaction in 122 patients with breast cancer, with or without bone metastases, and 59 age-matched healthy control subjects.


RESULTS
Serum miR-10b concentrations were significantly higher in patients with  bone metastases than in patients without bone metastases or control subjects. Serum miR-10b had an area under the receiver operating characteristic curve for the presence of bone metastases of 0.769, with 64.8% sensitivity and 69.5% specificity.


CONCLUSIONS
These results suggest that serum  miR-10b may be a useful biomarker for the identification of bone metastatic breast cancer.
Department of Orthopaedics, The Luhe Teaching Hospital of the Capital Medical University, Beijing, China.
F-L
FL
Zhao
G-D
GD
Hu
X-F
XF
Wang
X-H
XH
Zhang
Y-K
YK
Zhang
Z-S
ZS
Yu
D000328:Adult; D000368:Aged; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D001859:Bone Neoplasms / Q000097:blood / Q000556:secondary*; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology; D016022:Case-Control Studies; D017931:DNA Primers; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D012372:ROC Curve; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D017931:DNA Primers; C547183:MIRN10 microRNA, human; D035683:MicroRNAs